Disclosed are methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration of low dose interleukin-2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as a treatment of major depressive disorder.

Disclosed are methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration of low dose interleukin-2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as a treatment of major depressive disorder.

The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.

The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.

The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.

Disclosed are a pharmaceutical composition and an application thereof. The pharmaceutical composition of the present invention comprises the following components in parts by weight: 2-20 parts of phenolic acids, 0.5-5 parts of flavonoids, 0.005-0.5 part of tanshinones, 5-20 parts of saponins, and 10-18 parts of volatile oils. The pharmaceutical composition has the functions of protecting against myocardial damage and treating heart failure.

A composition comprising, for example, 1 wt-% to 10 wt-% curcumin or turmeric; 50 wt-% to 60 wt-% ginger; 10 wt-% to 20 wt-% ashwagandha; and 25 wt % to 30 wt % Tulsi herb, relative to the total weight of curcumin, ginger, ashwagandha and Tulsi herb, and methods of making and using the compositions, are provided.

A composition comprising, for example, 1 wt-% to 10 wt-% curcumin or turmeric; 50 wt-% to 60 wt-% ginger; 10 wt-% to 20 wt-% ashwagandha; and 25 wt % to 30 wt % Tulsi herb, relative to the total weight of curcumin, ginger, ashwagandha and Tulsi herb, and methods of making and using the compositions, are provided.

The present invention relates to a nasal spray with mucoadhesive properties that gels in situ containing the psychedelic tryptamines DMT or 5-MeO-DMT or pharmaceutically acceptable salts or derivatives thereof, which can be used for personalized treatment of neurological and psychiatric disorders.

The present invention relates to a nasal spray with mucoadhesive properties that gels in situ containing the psychedelic tryptamines DMT or 5-MeO-DMT or pharmaceutically acceptable salts or derivatives thereof, which can be used for personalized treatment of neurological and psychiatric disorders.